Key result
Elevated plasma PCSK5 post-MI predicts six-month cardiac function improvement with an AUC of ~0.82.
Why the study?
PCSK5 is essential for heart development, but its role in myocardial infarction remains unexplored.
Does PCSK5 promote angiogenesis and cardiac repair after myocardial infarction?
Observational (n=58)
Does PCSK5 promote angiogenesis and cardiac repair after myocardial infarction?
Effect estimate: AUC 0.822 (95% CI 0.651-0.992)
PCSK5 is identified as a pro-angiogenic factor secreted by endothelial cells that promotes cardiac repair post-MI, highlighting its potential as a therapeutic target for ischemic diseases.
Supports PCSK5 as prognostic biomarker post-MI; hypothesis-generating for endothelial delivery or semaglutide in repair, pending trials.
PCSK5 (proprotein convertase subtilisin/kexin 5) is essential for heart development. However, its role in myocardial infarction (MI) remains unexplored. In this study, we found that the plasma levels of PCSK5 were elevated in MI patients and exhibited potential in predicting cardiac function improvement. PCSK5 expression was upregulated in cardiac endothelial cells (ECs) of MI patients. Pcsk5 deficiency in ECs impaired angiogenesis and cardiac recovery post-MI, and delayed tissue repair following hindlimb ischemic injury in male mice. In contrast, the endothelial-specific Pcsk5 delivery enhanced angiogenesis and cardiac function post-MI. Mechanistically, PCSK5 directly cleaved VEGFA, activating its signaling and promoting angiogenic activity. The residues Arg158 and Asn164 of PCSK5 were crucial for its function. Semaglutide increased vascular densities and cardiac function post-MI, partially through EC-derived Pcsk5 in male mice. This study identified PCSK5 as a pro-angiogenic factor secreted by ECs, with the potential to become a therapeutic target for ischemic diseases. The authors identify PCSK5 as a pro-angiogenic factor from endothelial cells, with the potential to become a therapeutic target for ischemic diseases. Semaglutide enhances angiogenesis and tissue repair in mice post-myocardial infarction, partly via PCSK5.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) conducted an observational in Acute Myocardial Infarction (n=58). Plasma PCSK5 levels vs. Healthy controls was evaluated on Prediction of cardiac function improvement (AUC 0.822, 95% CI 0.651-0.992). Plasma PCSK5 levels were elevated in patients with acute myocardial infarction and predicted cardiac function improvement at six months with an area under the curve of 0.822.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: